Claims for Patent: 9,259,388

Summary for Patent: 9,259,388

Title:	Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Abstract:	The invention relates to a method for treating overactive bladders and a device for storing and administering non-occluded oxybutynin topical compositions.
Inventor(s):	Gochnour; Scott (Salt Lake City, UT), Subramanyan; Venkatesh (Salt Lake City, UT), Kimball; Michael W. (Salt Lake City, UT)
Assignee:	Watson Pharmaceuticals, Inc. (Salt Lake City, UT)
Application Number:	14/059,671
Patent Claims:	1. A method of minimizing adverse experiences associated with oxybutynin therapy comprising the steps of: a. providing a device for storing and administering a non-occluded oxybutynin topical composition i. wherein the device comprises: 1. a non-occluded oxybutynin topical composition comprising: a. oxybutynin; b. a thickening agent; and c. 50% or more based upon the weight of the non-occluded oxybutynin topical composition of a solvent; 2. a reservoir for the non-occluded oxybutynin topical composition; and 3. a laminate surrounding the reservoir and non-occluded oxybutynin topical composition comprising: a. a first polymer that is in contact with the non-occluded oxybutynin topical composition; and b. a metal foil bound to the first polymer layer; and 4. a notch or partial scoring of the laminate surrounding the reservoir and non-occluded oxybutynin topical composition wherein the notch or partial scoring facilitates the opening of the device for dispensing the non-occluded oxybutynin topical composition from the device; and ii. wherein the device can withstand 30 pounds of pressure without bursting when squeezed between two platens of a motorized test stand and when the device is stored at 25.degree. C. and 60% relative humidity for twenty-six weeks the non-occluded oxybutynin topical composition contains not more than 0.2% of phenylcyclohexyl glycolic acid ethyl ester (PCGE); not more than 2.0% phenylcyclohexylglycolic acid (PCGA) and there is not more than a 20% change in the solvent content; and b. dispensing a single or daily dose of the oxybutynin composition from the device. 2. The method according to claim 1, wherein the non-occluded oxybutynin topical composition is a gel, cream or lotion. 3. The method according to claim 1, wherein the non-occluded oxybutynin topical composition is a gel. 4. The method according to claim 1, wherein the non-occluded oxybutynin topical composition comprises about 2% to about 20% oxybutynin based upon the total weight of the composition. 5. The method according to claim 1, wherein the non-occluded oxybutynin topical composition comprises about 3% to about 15% oxybutynin based upon the total weight of the composition. 6. The method according to claim 1, wherein the non-occluded oxybutynin topical composition comprises about 4% to about 15% oxybutynin based upon the total weight of the composition. 7. The method according to claim 1, wherein the non-occluded oxybutynin topical composition comprises about 8% to about 12% oxybutynin based upon the total weight of the composition. 8. The method according to claim 1, wherein the oxybutynin is a pharmaceutically acceptable salt of oxybutynin. 9. The method according to claim 1, wherein the oxybutynin is oxybutynin chloride. 10. The method according to claim 1, wherein the non-occluded oxybutynin topical formulation further comprises at least one selected from the group consisting of chelating agents, surfactants, permeation enhancers, preservatives, anti-microbial agents, antibacterial agents, antioxidants, lubricants and mixtures thereof. 11. The method according to claim 1, wherein the adverse experiences associated with oxybutynin therapy are selected from the group consisting of dry mouth, abdominal pain, dry nasal mucous membrane, dry sinus mucous membrane, constipation, diarrhea, nausea, somnolence, dizziness, impaired urination, increased post void residual volume, urinary retention, and combinations thereof. 12. The method according to claim 1, wherein the non-occluded oxybutynin topical formulation is suitable for application to a skin surface. 13. The method according to claim 12, wherein the skin surface is selected from the group consisting of abdomen skin surface, thigh skin surface, arm skin surface and combinations thereof. 14. The method according to claim 1, wherein the device contains 0.25 g to 5 g of the non-occluded oxybutynin topical formulation. 15. The method according to claim 1, wherein the device contains 1 g of the non-occluded oxybutynin topical formulation. 16. The method according to claim 1, wherein the solvent is an organic solvent or a mixture of an organic solvent and water. 17. The method according to claim 1, wherein the organic solvent is an alcohol. 18. The method according to claim 17, wherein the alcohol is selected from the group consisting of methanol, ethanol, isopropyl alcohol, benzyl alcohol, propanol and mixtures thereof. 19. The method according to claim 1, wherein the non-occluded oxybutynin topical composition is a gel, wherein the oxybutynin is oxybutynin chloride and wherein the solvent is a mixture of ethanol and water. 20. The method according to claim 1, wherein the oxybutynin is oxybutynin chloride that is present in an amount of 10.0% w/w of the non-occluded oxybutynin topical composition.